A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.

A Phase I, Randomized, Observer-blinded, Placebo-controlled and Dose-escalation Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of a SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.

This is a phase I, randomized, observer-blinded, placebo-controlled and dose-escalation clinical trial to evaluate the safety, tolerability, immunogenicity and immune persistence of SYS6006 (SARS-CoV-2 mRNA Vaccine) in 18-59 year old healthy population.

Study Overview

• Status: Active, not recruiting
• Conditions: SARS-CoV-2
• Intervention / Treatment: Biological: 20 μg dose of SYS6006; Biological: 30 μg dose of SYS6006; Drug: Placebo

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Jiangsu
    • Nanjing, Jiangsu, China
      • Sir Run Run Hosipital Nanjing Medical University
  • Zhejiang
    • Hangzhou, Zhejiang, China
      • Shulan（Hangzhou） Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 59 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Age at the time of the first dose of vaccine: 18 to 59 years;
2. Axillary body temperature is less than 37.3 degree centigrade on the day of enrollment;
3. Based on the medical history and relevant physical examination and laboratory examination results (normal or abnormal but no clinical significance), the investigator clinically determined that the patient was in good health;
4. Has independent judgment, and participate voluntarily and sign an informed consent form.

Exclusion Criteria:

1. Has a history of SARS-CoV or SARS-CoV-2 infection, or close contact with SARS-CoV-2 infected persons (nucleic acid test positive) or living abroad within 30 days before screening;
2. Positive SARS-CoV-2 antibody test;
3. Previous history of allergy to acetaminophen or vaccination(eg, acute allergic reaction, urticaria, dyspnea, angioneurotic edema, or abdominal pain);
4. Has a history of COVID-19 vaccination, or have received other inactivated or recombinant vaccines within 7 days, or received live attenuated vaccines within 14 days,before the first dose;
5. Has a medical history or family history of epilepsy, convulsions, neurological diseases and psychiatric diseases;
6. Is contraindicative for intramuscular injection，such as: diagnosed thrombocytopenia, any coagulation disorders, or receiving anticoagulant therapy;
7. Has known or suspected serious disorders judged by the Investigator, including but not limited to respiratory disorders (pulmonary failure, etc.), liver and kidney disorders, cardiovascular disorders (cardiac failure, severe hypertension, etc.), malignant tumors, infections or allergic skin disorders, HIV infection, or in the acute infection or chronic disease activity period (within 3 days before vaccination);
8. Has chronic diseases (such as Down syndrome, sickle cell anemia, neurological disorders and Guillain-Barre syndrome, excluding stably controlled diabetes/hypertension) that are not suitable for this study at the discretion of the Investigator;
9. Has known immunocompromised conditions diagnosed in hospital before enrollment, or functional aspleen or splenectomy caused by any condition;
10. For women of childbearing potential: positive pregnancy test, being in pregnancy or breastfeeding, or have a pregnancy plan within one year;men: whose spouses is of childbearing potential and has a pregnancy plan within 1 year;
11. Is participating in other clinical trials or plan to participate in other clinical trials during the study period;
12. Has received immune enhancement or immunosuppressive therapy within 3 months before the first dose of vaccine (continuous oral or instillation for more than 14 days); or received whole blood, plasma and immunoglobulin therapy within one month;
13. Is unlikely to adhere to the study procedures or keep appointments at the discretion of the investigators;or plan to permanently relocate before the end of study; or plan to leave the resident location for a long time at the scheduled visit; or has any other conditions that are inappropriate for participation for this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Placebo IM, on day 0 and day 21.	Drug: Placebo; Placebo IM on day 0 and day 21.
Experimental: Vaccine group 1; 20 μg dose of SYS6006 vaccine IM, on day 0 and day 21.	Biological: 20 μg dose of SYS6006; 20 μg dose of SYS6006 vaccine IM on day 0 and day 21.
Experimental: Vaccine group 2; 30 μg dose of SYS6006 vaccine IM, on day 0 and day 21.	Biological: 30 μg dose of SYS6006; 30 μg dose of SYS6006 vaccine IM on day 0 and day 21.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
adverse events associated with the study intervention	From the first dose through 30 days following the second dose.
Adverse events, including solicited and unsolicited events	From the first dose through 30 days following the second dose.

Secondary Outcome Measures

Outcome Measure	Time Frame
Serious adverse events (SAE)	from the first dose through 12 months after the second dose.
Adverse events of special interest (AESI)	from the first dose through 12 months after the second dose.
Geometric mean titer (GMT), geometric mean increase (GMI) and seroconversion rate (SCR) of anti-SARS-CoV-2 antibody (specific IgG antibody and neutralizing antibody)	14 days after the first dose; 7 days, 14 days, 30 days, 90 days, 180 days and 360 days after the second dose
Laboratory test related adverse events	4 days following each dose

Collaborators and Investigators

• Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Investigators: Principal Investigator: Guiling Chen, Shulan (Hangzhou) hospital; Principal Investigator: Xiang Lu, Sir Run Run Hosipital Nanjing Medical University; Principal Investigator: Yuwen Su, Sir Run Run Hosipital Nanjing Medical University; Principal Investigator: lanjuan li, Shulan (Hangzhou) hospital

Study record dates

Study Major Dates

• Study Start (Actual): April 27, 2022
• Primary Completion (Actual): July 9, 2022
• Study Completion (Anticipated): October 1, 2023

Study Registration Dates

• First Submitted: April 28, 2022
• First Submitted That Met QC Criteria: April 28, 2022
• First Posted (Actual): April 29, 2022

Study Record Updates

• Last Update Posted (Actual): May 24, 2023
• Last Update Submitted That Met QC Criteria: May 23, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: SYS6006-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No